This program has concluded – check this page for information on our upcoming conferences!
The following speakers, panelists and moderators participated at DUBLIN 2016, held April 12-14, 2016 at the Shelbourne Hotel in Dublin, Ireland.
Senior Vice President, New Ventures & Business Development, LivaNova Group
Edward Andrle is Senior Vice President of New Ventures & Business Development at LivaNova. Previously, Andrle has served at Sorin Group as Vice President of Strategy & Business Development since 2010.
Andrle had a successful career in the medical device industry, where he also became an entrepreneur and a CEO of start-up companies like Teramed (endovascular stent-graft), Myocor (mitral valve surgery) and StarFire Medical (neurovascular technology). Prior to this, Andrle spent 5 years as a Vice President at Boston Scientific, where he led a new business unit focused on peripheral vascular catheters and guidewires that accounted for over $100 million in sales.
CEO of MedTech Europe, Eucomed, EDMA – MedTech Europe
Serge Bernasconi is Chief Executive Officer of MedTech Europe, EDMA and Eucomed. MedTech Europe is an alliance of European medical technology industry associations. EDMA is the European Diagnostic Manufacturers Association, and Eucomed is the European Medical Technology Industry Association.
Serge has more than 30 years experience in the world of pharmaceuticals and medical devices, working for companies such as Johnson & Johnson, Schering Plough in the US and Europe, and more recently Medtronic. In his capacity as President & International Regional Vice President of Medtronic France, he was elected President of APIDIM (The French Association for the Promotion of Innovation in Medical Devices), and Vice President and Treasurer of SNITEM (French Medical Technology Industry Association).
Investment Director, Endeavour Vision
Daniel Bertholet is an Senior Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in ReShape Medical, Sophia Genetics, PneumRx (sold to BTG), Symetis, CeQur, Nfocus (sold to Covidien), Endoart (sold to Allergan), Thommen Medical (exited), Neocutis (sold to Merz Pharma), Novalar Pharmaceuticals (exited), Molecular Partners (IPO) and Kuros (merged with Cytos), Biosurgery. He also participated in investments and/or follow-on investments in Native Networks (sold to Alcatel), eProject/Daptiv (exited), Paion (IPO), Nexx Systems (sold to Tokyo Electron) and Novimmune.
Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.
Senior Investment Manager – Private Equity, Ireland Strategic Investment Fund
James Brennan is Head of Venture Fund Investments at the Ireland Strategic Investment Fund (ISIF). The ISIF is an Irish sovereign development fund with discretionary assets under management of €7.8 billion, set up in December 2014 to invest on a commercial basis in support of economic activity and employment in Ireland. The ISIF populates its €500 million allocation to venture capital funds through commitments to local and international partnerships, and actively seeks opportunities to provide direct equity to suitable later stage VC-backed companies where its double bottom line mandate can be achieved.
Previously James was a Senior Manager on the private equity team of the Irish National Pensions Reserve Fund, the predecessor to the ISIF and a more traditional long term sovereign wealth fund where he focused on venture, growth and buyout fund investments in North America and Europe. James graduated from University College Dublin with a BSc Theoretical Physics and an MSc Computational Science, and is a CFA charterholder.
Operating Partner, Imperial Innovations
With 35 years pharmaceutical, biotech and medtech experience gained in commercial, product development, supply chain, strategic leadership and corporate executive roles, Simon is a serial entrepreneur in early stage healthcare businesses. As CEO of ApaTech Ltd, a QMUL spinout, he developed a world leader in orthobiologics prior to its sale to Baxter for $330m in March 2010.
Prior to joining ApaTech in 2004 Simon was a Main Board Director of Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international commercial, supply chain and strategic development leadership roles.
He is currently a Non-Executive Director of ReNeuron plc, Creo Medical Ltd and investee company Stanmore Implants Worldwide Ltd. In addition he is Chairman of investee company Veryan Medical Ltd and part-time CEO of Calon Cardio-Technology Ltd.
General Partner, Lightstone Ventures
Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), Holaira, MicroVention (acquired by Terumo), Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome and TranS1 (NASDAQ: TSON).
Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a Lecturer at the Amos Tuck School of Business Administration at Dartmouth College where he also sits on the Tuck MBA Advisory Board. In addition, Mike is a Director on the National Venture Capital Association (NVCA) Board of Directors where he is active in helping to shape policy affecting both innovation and healthcare. Lastly, Mike has been heavily involved with several programs at Stanford University including the Stanford Biodesign Program and, more recently, the Stanford Center for Clinical and Translational Research and Education (Spectrum) where he currently serves as a Member of the Oversight Committee.
Co-Editor-in-Chief, The MedTech Strategist
Managing Partner, Innovation In Medtech, LLC
David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.
Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time.
Vice President of Corporate Development, Medtronic
Chris is Vice President of Corporate Development for Medtronic, with responsibility for acquisitions, dispositions and minority investments. During 2014, Chris led the corporate development efforts for Medtronic’s $50B acquisition of Covidien as well for Medtronic’s acquisition of both Sapiens and NGC, for $200MM and $350MM respectively.
Prior to 2014, Chris was CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs, Ally, Macquarie Capital and Terex. From 1995 to 2011, Chris led M&A teams within several businesses at GE Capital, closing acquisitions totaling more than $60B across 200+ transactions in the US, Canada, Europe, Asia and Latin America.
Former CEO, Twelve
Twelve’s former CEO is Andrew Cleeland, who is also vice chairman of The Foundry. He previously led renal denervation start-up Ardian, which Medtronic acquired for $800 million plus undisclosed commercial milestones in January 2011. Ardian also came out of The Foundry.
General Partner, Kreos Capital
Aris is a General Partner at Kreos Capital, Europe’s largest and leading provider of specialty finance to growth companies from early- to late-stage. Previously he was the founder and Investment Director of London-based NBGI Ventures, the only European venture capital firm investing exclusively in medical technology companies. Aris currently serves on the boards of a number of medtech companies including: Advanced Cardiac Therapeutics, 2010 Perfect Vision, Endoscopic Technologies, EOS Imaging, Dysis Medical Limited, Reverse Medical and SuperSonic Imagine. Aris started his career at Bankers Trust where he was a structurer of innovative derivative products. He has more than 14 years of experience with European venture capital and private equity, including Deutsche Bank’s and Credit Suisse First Boston’s funds. He holds Mechanical Engineering degrees from Imperial College and MIT as well as an MBA from Insead.
Investment Manager, European Investment Fund
Adelaide Cracco is an Investment Manager at the European Investment Fund (EIF), institution that supports entrepreneurship and innovation across Europe, providing financing to SMEs as a cornerstone investor in venture and growth capital funds. Prior to joining the EIF, Adelaide was Managing Director of the Finaves seed capital funds based in Barcelona, where she oversaw Finaves’ investments in 20 early stage ventures and launched the firm’s fourth fund, Finaves IV.
Before working for Finaves, Adelaide was part of the founding management team and Finance Director of Mixta Africa a real estate group specialized in social and economic housing development projects with activities across the African continent and backed by Morgan Stanley and the IFC (World Bank Group). Adelaide developed most of her early career in corporate finance and private equity starting off as an analyst at the Inter-American Investment Corporation and later working for Clairfield International in Spain where she was responsible for transactions in the pharmaceutical industry, among other sectors.
Partner, Gilde Healthcare Partners
Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde’s investment in Definiens, Sapiens and Qinec. He currently represents Gilde on the board of Qinec. He served on the supervisory board of Definiens and Sapiens until trade sale.
Prior to joining, he was a Venture General Manager and Head of Business Development & Strategy within Philips’ Corporate Venturing unit in Healthcare. On top of shaping the strategy, he was responsible for selecting new investment opportunities. He also started and lead two ventures in the fields of cardiology and sepsis. He also served as an Engagement Manager at McKinsey & Company advising leading High Tech companies on strategies for growth and strategic marketing.
Prior to this, he cofounded a Nanotech company in the Silicon Valley after serving as a Fellow at the Lawrence Berkeley National Lab. He earned a PhD in Physics from the University of Cambridge in the UKand was a Post-Doc in Nanotechnology at the University of California, Berkeley.
Hanson Gifford III
Managing Partner, The Foundry
Mr. Gifford co-founded The Foundry in 1998. His key activities include inventing and identifying new technologies, and forming, financing, staffing, and providing ongoing support for The Foundry’s new companies.
Prior to The Foundry, Mr. Gifford was VP of R&D at Heartport. From 1993-1998, he built and led a 62-person team developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. Heartport had a successful public offering in 1996. In 1992, Mr. Gifford co-founded and served as managing director of Bavaria Medizin Technologie, GmbH, a German source of catheters for interventional cardiology. In 1990, Mr. Gifford served as President of Cardiovascular Therapeutic Technologies, which was acquired by Eli Lilly in 1991. From 1985-1990, Mr. Gifford worked at Devices for Vascular Intervention (DVI), where he served in various engineering, clinical research and marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics.
Mr. Gifford is a co-inventor on over 225 issued US patents. He earned his B.S. degree in mechanical engineering from Cornell University. Mr. Gifford serves as Chairman of Forsight Labs, and is a Director of Miramar Labs, Twelve, Cotera, FIRE1, Forsight Vision 4 and Forsight Vision 5. He is also a Venture Partner with Lightstone Ventures.
Director, Surgical Endoscopy Group, Medical Systems Division, Olympus
Managing Director, RCT Ventures, and Head, MedTech Innovator
Paul Grand is a Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc., which is focused on early-stage biomedical companies. At RCT, he is responsible for sourcing RCT’s investments in medical devices and representing RCT on the boards of its portfolio companies. Grand is actively involved in programs to encourage bio-entrepreneurship, innovation and commercialization of early stage technologies. He has lectured, judged business plans, and mentored students and scientists at numerous universities, including UCLA, Stanford, USC, and UCSF. Grand serves as an investment advisor to the LARTA NIH Commercialization Assistance Program for SBIR program awardees. He is on the Oversight Committees for the Coulter Translational Research Partnership Programs at USC and University of Washington. Grand is a reviewer for proof of concept and commercialization-focused funding programs for the University of California system-wide, USC, University of Utah and University of Colorado.
Founder and CEO, InnoVentures Medical Accelerator
Ty is the founder and Executive Managing Partner of Gateway Medical Innovation Center in Shanghai. Ty is also the founder and CEO of InnoMed, a Santa Clara, CA and Shanghai based medical device company.
Ty has a broad academic and industrial experience. Started his industry career at Guidant in 1996 with a strong focus on cardiovascular interventional devices. He has managed numerous technology innovation and product development programs with increasing responsibilities. Prior to his entrepreneur endeavor, Ty was the President and General Manager at Vascore Medical in Suzhou, China, Director of Endovascular New Product Development and Director of Worldwide Franchise R&D for New Product Development and Commercialization at Cordis (a Johnson and Johnson company) in Miami Lakes, Florida, and the Program Manager of Coronary Drug-Eluting Stent at Guidant in Santa Clara, California.
Ty received his medical education from China Medical University. Served as a legislative staff with the China National Congress Committee on Health before pursuing his graduate education in health management at Yale University. Completed his post-doctoral training on medical oncology at Yale School of Medicine in New Haven, CT and worked at Cancer Institute of New Jersey before joining the medical device industry. Ty has relocated to Shanghai in 2005 to focus on his ventures in China.
A graduate of Yale School of Public Health ( MPH), Mr. Hu received his medical education from China Medical University in Shenyang and finished his post-doctoral training in medical oncology at the Yale Medical School. Before moving back to Shanghai in 2005, he was the R&D director at Cordis Corp in Miami Lakes, Florida and the program manager for Guidant Corporation (now Abbota Vascular) in Santa Clara, California.
CEO and Co-Founder, Symap Medical
Kewen Jin is a serial entrepreneur in China with an extensive background at U.S.-based venture capital and pharmaceutical companies.
He is the CEO and co-founder of Symap Medical, a medical device company based in China. He is also chairman of BayHelix, an organization of Chinese life-sciences business leaders in China and the U.S., and a special advisor to the Bill & Melinda Gates Foundation in its China R&D matters. In the last 15 years, Jin co-founded and served as CEO of several companies in the areas of drug discovery, medical devices, healthcare services and contract research organizations. He has been an advisor to many pharmaceutical, healthcare companies, consulting and investment firms.
Jin also helped two leading life-science parks in China – Shanghai Zhangjiang and Suzhou Biobay – to develop and implement strategic plans, and was the founding chair of the Shanghai CRO Association. Previously, he was a marketing and international operations executive with Wyeth in the U.S. and in China. Jin studied medicine at the Shanghai Jiaotong University School of Medicine, molecular biology at Rockefeller University and finance at Columbia University.
Former CEO, Biosensors
Chief Development Officer, CVRx, Inc.
Dr. Kieval is a company founder and served as President and CEO of CVRx from its inception in 2001 through October, 2006. He has over 20 years of medical device industry experience from previous positions including Business Development Director at ProtoStar, Inc. and divisional Medical Director at Medtronic, Inc. He completed his undergraduate and graduate training at The University of Pennsylvania, where he received doctorate degrees in Veterinary Medicine and in Physiology. In 2006, Dr. Kieval was named an Innovator of the Year by Twin Cities Finance & Commerce. He currently holds over fifty patents.
Director, Strategic Technology Partnerships, BD Technologies
Albert Lauritano is Director, Technology Licensing & Collaboration for BD Technologies, the corporate technology innovation center for BD. He is responsible for technology scouting, acquisition, management, partnership and commercialization activities including the management of BD’s life science incubator and execution of innovation strategy. He is also a member of BD’s Corporate Development and University Relations MBA Recruitment teams. Al joined BD in 2003 and has over 35 years of experience in the pharmaceutical, biotechnology and medical technology industries.
Prior to joining BD, he held executive business development positions at Amylin Pharmaceuticals, Icagen and D-Pharm Ltd after starting his career at Novo Nordisk Pharmaceuticals where he served in senior clinical, marketing and business development positions in the US, Canada, Europe and Japan. Al has a BS in Biology from Fairleigh Dickinson University and an MS in Pharmacology from Rutgers University; he has published widely in the field of diabetes. He is a Certified Licensing Professional and a member of Licensing Executive Society and Association of University Technology Managers.
Partner/Entrepreneur in Residence, MD Start
Tim Lenihan is the Co-Founder and Partner of MD Start, where he evaluated over 700 ideas and founded 4 companies, 3 of which were series A funded. Recently, Tim has been the acting CEO of LimFlow, the 4th company created and incubated by MD Start I which focuses on critical limb ischemia and aims at restoring blood flow to the limb. Prior to founding MD Start in 2010, Tim was CEO and Founder of Contract Medical International GmbH (CMI) a contract developer and manufacturer of catheter based medical devices headquartered in Dresden Germany with facilities in both Germany and the Czech Republic.
Tim has worked in various engineering and regulatory positions in the medical device industry over the last 26 years both in the US and Europe. He has worked with researchers, entrepreneurs and small companies to develop, obtain approval, manufacture and launch of variety of medical devices in the field of Critical Care Medicine, Interventional Cardiology and Radiology and Respiratory Care. Tim is Director of the Board of CMI (Germany) and CathPrint (Sweden). He holds his bachelor’s degree in biomedical engineering from Rensselaer Polytechnic Institute and his master’s degree from the University of Pennsylvania.
Partner, Lightstone Ventures
Jason Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, Spinewave and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.
Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014) as well as actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott Labs). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.
Howard Levin, MD
Co-Founder, President, and Chief Scientific Officer, Coridea
Howard Levin, MD is a cardiologist and an expert in integration of cardiac, respiratory and renal physiological into novel therapeutic solutions. Coridea is an idea generator, technology incubator and consulting firm that applies established technologies to new targets in the cardio-renal and cardio-pulmonary fields. Behind the venture – established in 1998 – are inventors and entrepreneurs Howard Levin, MD, a cardiologist, and Mark Gelfand, a biomedical engineer, who met at Johns Hopkins University in the late 1980s.
The start-up companies created through Coridea and umbrella companies, including CHF Solutions, Ardian and Cardiac Concepts, have secured over $200 million in venture capital financing. Coridea generated 47 issued U.S. patents. The company’s patents have been licensed by EValve, Zoll Medical, Nephros, PLC Medical, Biophan and others. Coridea’s consulting client list includes Columbia and Johns Hopkins Universities, Clarus Ventures and Eastern Associates.
Co-Editor-in-Chief, The MedTech Strategist
Managing Partner, Innovation In Medtech LLC
Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the IN3 medical device partnering conference series. Stephen joined Windhover Information in 1997, where as Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.
Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).
Partner & CFO, Fountain Healthcare Partners
Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science.
Justin began his career as a research analyst at NCB stockbrokers in 1985. During this time, Justin had analytical responsibility for 13 companies accounting for 25% of the capitalisation of the Irish Stock Exchange. In 1988, Justin joined the Corporate Finance group of Fyffes plc where his activities included the execution of a number of M&A and financial transactions. He subsequently held a similar senior Corporate Finance role with the Jones Group plc for several years before returning full time to Trinity College to complete an MBA.
After completing his MBA in 1997, Justin co-founded Legend Care and developed a series of medical hosiery devices including a preventive foot care device for diabetic foot disease which is presently in a physician led 400 patient longitudinal multi-centre RCT in the US and the UK, funded by the NIDDK, US National Institutes of Health.
Justin has a particular interest in the medical device sector. He led the firms investments in Vivasure Medical and Neuravi and is a member of the board of directors of both companies.
Managing Consultant – Medical, Intertek
Michael Lynch is a seasoned medical device product development professional with over 30 years in the field. His experience spans a diverse range of products from high volume disposable drug delivery systems to orthopaedic implants as well as electro-mechanical capital equipment. Michael has managed the product development process from concept through full scale manufacture. The marketing and manufacturing responsibilities he has had in other roles provides insight into the needs of these functions during product development. His breadth of experience provides a comprehensive understanding of the product lifecycle of medical devices.
Richard Mason, MD
Head Johnson & Johnson Innovation
Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015.
Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions.
Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).
Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.
Investment Director, Atlantic Bridge Capital
Dr. Helen McBreen is Investment Director at Atlantic Bridge Capital. Having successfully sourced, formed and financed dozens of IP rich technology ventures and with a credible investment track record Helen brings her expertise in early stage investing to Atlantic Bridge Capital.
Prior to joining Atlantic Bridge Capital, Helen was a member of the NDRC Investment Committee playing a key role in the allocation of €45m capital into new technology ventures with a particular focus on ventures in energy, health and ICT.
In 2014, Helen successful founded ‘FutureHealth’ in partnership with EY, ICON, UCD and Enterprise Ireland, with the objective of finding new health tech startups across Ireland.
Helen holds a number of Board Member and Advisory positions including: eHealth Ireland, HealthXL Platform, UCD MSc Innovation, Entrepreneurship and Design, Enterprise Ireland Business Advisor in International Selling, UCD VentureLaunch and is a mentor to a number of tech startups.
Helen is particularly interested in technologies based on AI, robotics, big data & data science, bioinformatics, medtech, neuroscience, connected health and nanotech.
Director Venture Investments, Norgine Ventures
Julien Michaux joined Norgine Ventures from Lazard where as a member of the Healthcare M&A team he advised many European and US clients on merger and acquisition transactions. Julien joined Lazard in 2005 from J&J Pharmaceuticals where he worked as part of the M&A team. Julien has 11 years of experience in the Healthcare industry. He started his career with Procter & Gamble.
Julien holds an MS in Engineering from ICAM in France and an MBA from the Anderson School at UCLA.
Head Associate, Syndicate Room
Fran is responsible for management of dealflow and liaison with entrepreneurs.
She graduated from St John’s College, Cambridge, where she read Part I History; Part II Psychology, before completing a Graduate Diploma in Law in London. Fran has previously worked with the legal team responsible for preparing victim and witness statements for the Leveson Inquiry, and within the schools and education department of the London Borough of Ealing Council.
She joined SyndicateRoom to immerse herself in the unique challenge (and buzz!) that comes from working at a young, rapidly growing company, within an exciting and disruptive industry.
Partner, Seroba Life Sciences
Alan O’Connell is a Partner at Seroba Life Sciences. He has a background in product and business development in the pharmaceutical and biotechnology industries.
Prior to joining the firm in 2003, Alan worked in a variety of product and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and he also spent time in the Pharmacovigilance section at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation.
Alan graduated with a Ph.D. (neurophamacology) from the National University of Ireland, Galway in 1994 and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals.
Dr O’Connell sits on the boards of: Ario Pharma; Crescent Diagnostics; Heart Metabolics; Opsona Therapeutics; Veryan Medical; and Xention.
Stephen Oesterle, MD
Venture Partner, New Enterprise Associates
and Corporate Advisor to Temasek Holdings and EQT
Steve joined NEA in 2015 as a Venture Partner on the Healthcare team where he focuses on the Medical Device investing practice. Prior to joining NEA, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic, Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.
Steve graduated summa cum laude from Harvard and received his medical degree from Yale; he completed his internship and residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.
Partner, Eugene F. Collins
John Olden is a partner in the Firm’s Corporate Department. His practice areas are mergers and acquisitions, venture capital, capital markets, company and Partnership law. His mergers and acquisitions experience covers both public and private companies.
In the area of venture capital, he has advised on the establishment and marketing of venture capital funds, relationships between the general partner and limited Partners, investment by venture capital funds into Irish and other businesses and he has advised Irish companies on the raising of venture capital finance.
Partner, Seroba Life Sciences
Daniel O’Mahony is a Partner at Seroba Life Sciences, a pan European life sciences VC. Seroba invests in companies developing new medical devices or therapeutics.
Daniel brings a wealth of experience in product development, strategic planning, licensing, intellectual property management and commercialization across the Medtech, pharma and biotech industry sectors and in venture capital and corporate investments. He previously worked in Elan Corporation plc and Taro Pharmaceuticals Inc. In 2005 he established the Technology Transfer Office at NUI, Galway.
Daniel graduated with a Ph.D. from the National University of Ireland, Cork and holds a business degree in technology management from the Smurfit Business School, University College Dublin. He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College Dublin. He has published in several scientific journals, is co-inventor on numerous patent families and is a regular panel member at major international medtech conferences. He is a former member of the Irish government’s Innovation Task Force intellectual property strategy sub-group.
Dr O’Mahony currently sits on the boards of Novate Medical and PQ Bypass Irl. Ltd. He also sat on the boards of Apica Cardiovascular, Covagen and Stokes Bio prior to their acquisitions by Thoratec, Cilag (a part of the Janssen Pharmaceutical companies of the Johnson & Johnson Group) and Life Technologies, respectively.
Managing Partner, Sofinnova Partners
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Auris, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology). He has also invested in and is a board member of private companies ReCor, MD Start, Shockwave Medical, and Reflexion Medical and ProQR.
Partner, Head of U.S. Life Sciences Mergers and Acquisitions, EY
Ben Perkins is a Senior Managing Director and the U.S. Life Sciences Sector Leader for EY Capital Advisors, LLC. Ben has 18 years of lead-, co- and exclusive advisory experience in the Pharma, Biotech, Device and Diagnostic sectors. He has worked with clients on equity and debt financings, merger and acquisition transactions and partnership structuring. He joined EY from Merrill Lynch, where he served as a Managing Director, leading the West Coast Life Sciences practice. Ben has over $5B in completed financing work and $7B in completed M&A work in Life Sciences investment banking.
Martin Pfister, M.D.
Senior Investment Manager, High-Tech Grunderfonds Management
Dr. Martin Pfister studied biopharmacology at the University of Greifswald and New York University, and earned a doctorate in immunology at the University of Leipzig. Prior to joining High-Tech Grunderfonds Management, Pfister served as Managing Director of the Saxony State Ministry of the Economy and Labour’s coordination office for biotechnology & pharmaceuticals.
General Partner, Lightstone Ventures
Hank is a General Partner of Lightstone Ventures. He focuses on medical device investments out of the firm’s Menlo Park, CA office. Hank also serves as a General Partner at Morgenthaler Ventures which he joined in 2007 after more than 25 years in the life science industry. Prior to becoming a venture capitalist, he co-founded eight medical device companies. He has served as a director for nine companies that have had successful exits with a combined value in excess of $3 billion.
In August 2015, Medtronic announced plans to acquire Twelve, Inc. for $408 million and milestone payments of $50 million. In May 2014, Cardinal Health completed the acquisition of Access Closure for $320 million. In June 2014, Ulthera, Inc. acquired Cabochon Aesthetics in cash and milestone payments. Hank served as a board member of the three companies. In 2011, Medtronic completed the acquisition of Ardian for $800 million. Hank was a founder, helped incubate Ardian while at The Foundry, and served as a Director of the company. In 2010, Hank was a board member during the $785 million acquisition of Acclarent by Johnson & Johnson. Hank led the Lightstone investment and serves on the board of Earlens and Claret. He also serves on the boards of Morgenthaler portfolio companies – Holaira, Kona Medical, Miramar Labs and Setpoint.
VP, Discovery Advanced Technology, Edwards Lifesciences
Stan currently serves as Vice President, Advanced Technology & Discovery at Edwards Lifesciences. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT), of which he was co-founder, Executive Vice President and COO. PVT has pioneered the development of transcatheter heart valves.
Stan spent over 17 years of his medical device development career at Johnson & Johnson, where he held positions in Engineering, R&D and Business Development at Johnson & Johnson Interventional Systems (JJIS), SITE Microsurgical and Johnson & Johnson Ultrasound.
Vice President, New Business Development, Johnson & Johnson
Alan Rae is Vice President, New Business Development, for Johnson & Johnson Medical Devices group. He has more than 30 years of medical device experience with Johnson & Johnson, having led new business and product introductions in Europe, Asia Pacific, Latin America, and the U.S.
Partner, Earlybird Venture Capital
Previously Managing Director of Ethicon and Vice President (Europe) of Johnson & Johnson subsidiary Critikon.
Partner, Ysios Capital Partners
Josep L.l. Sanfeliu focuses on medtech investments and on structuring transactions.
Josep serves on the board of MedLumics, Dermalumics and CVRx. Formerly, he was board observer at Endosense and board member at Sabir Medical.
Josep has over 15 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual propertyrelated companies. Before joining Ysios, Josep worked for the pharma and healthcare industries, in areas such as business and corporate development. This included managerial positions at Almirall and SAR-Quavitae. Joe also worked at Cuatrecasas, KPMG and Eurohold Corporate Finance, where he was involved in mergers and acquisitions, and financing of innovation and technology.
Josep holds a degree in Law from Universitat Pompeu Fabra of Barcelona, a Master of Laws (LL.M) degree from the University of Michigan at Ann Arbor, and an MBA (Global Executive MBA) from IESE (University of Navarra).
Partner, Life Sciences, Edmond de Rothschild Investment Partners
Prior to joining the Edmond de Rothschild Group, Naveed was a Partner at Phase4 Ventures. His career spans medicine, investment banking and venture capital/growth equity. Before Phase4 Venture, he was part of a small initial founding group of investment professionals who helped to build a global healthcare investment business for Nomura with several hundred million dollars of invested capital. Naveed has been involved in over $1 billion of equity and debt financings in Europe, US and Japan. He has served as a Board director and observed on several Boards. Prior to his career in private equity, he worked for EFG Corporate Finance, KPMG and UK’s National Health Service. His academic qualifications include degrees in Medicine from Guy’s & St Thomas’s Hospital Medical School, London and accountancy from the Institute of Chartered Accountants, England & Wales.
Managing Partner, Peppermint Venture Partners
Dr. Stöckemann co-founder of Peppermint Venture Partners and one of the managing partners in the Charité Biomedical Fund. As a former General Partner in the international Healthcare Venture Team of 3i, he is a highly experienced venture capitalist. He has been active for more than 10 years in the Venture Capital industry and was responsible for more than 12 investments during his tenure at 3i. His track record at 3i includes the IPO of companies like Epigenomics, Jerini and Santhera as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion.
Dr. Stöckemann has been board member of Combinature, Epigenomics, Jerini, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He is currently Chairman of the boards of Humedics and Hematris. Prior to joining 3i, Dr. Stöckemann held leading positions in R&D and Business Development with large Pharma companies like Schering AG and ASTA Medica (a Degussa&Hüls group company). He holds a Ph.D in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU/Kellogg Northwestern University in the U.S.
General Partner, Wellington Partners
With over 20 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His fourteen years of investment activity have involved financing of some of the most successful European biotech, medtech, and diagnostics companies.
In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, today a listed company with a market cap of more than four billion euros. He was also responsible for the investments in Grandis (acquired by Novartis), NoemaLife (Borsa Italiana:NOE), Wavelight (acquired by Alcon), immatics as well as mtm laboratories (acquired by Roche).
Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians University in Munich.
Rainer studied medicine and economics and holds a doctorate in medicine as well as a master’s degree in economics.
Co‐Founder, Chairman & Managing Director, Accuitive Medical Ventures
As a co-founder of Accuitive Medical Ventures, Tom brings over 25 years of operating experience, as well as critical fundraising skills in the medical device industry. Tom co-founded the medical device incubator The Innovation Factory (TIF) and serves as its chairman. He was also a co-founder and chairman of Novoste Corporation, the intracoronary radiation therapy company. He was chairman and CEO of Novoste from its inception in 1992 and led the company through its initial public offering in 1996.
Through his role at The Innovation Factory, Tom has co-founded numerous companies including: AcuFocus, AqueSys, Halscion, Liposonix, Neuronetics, and, Sebacia. He was formerly the chairman of LipoSonix, prior to its sale. Tom holds nearly two dozen issued U.S. patents on medical devices. Before co-founding Novoste, Tom held positions with Novoste Puerto Rico, Arthur Young & Company and Key Pharmaceuticals in various business and project management roles. Tom holds a B.S. in Industrial Engineering from Purdue University and an M.B.A. from Indiana University.
Tom currently serves as a board member for MyoScience, Respicardia, and Sebacia.
William Wijns, MD
Chairman PCR and Chairman, PCR Innovators Day
William Wijns served on the Board of the European Society of Cardiology, the World Heart Federation and the European Association for Percutaneous Cardiovascular Interventions until August 2010. Currently Dr. Wijns is chair of Euro PCR.
He graduated in 1976 from the University of Louvain in Belgium where he trained as a cardiologist until 1981 (Professor J-M. Detry). He then joined the Thorax Center in Rotterdam (Professor P. Hugenholtz and P.W. Serruys) where he was actively involved with the first applications of nuclear cardiology, thrombolysis and coronary dilatation. After spending 1984 and 1985 as a Visiting Associate Professor of Radiological Sciences at UCLA (Professor H. Schelbert), Dr. Wijns returned to the University of Louvain in Brussels where he directed the cardiac PET program and became Clinical Professor of Cardiology.
In 1994, Dr. Wijns joined the group in Aalst as Co-Director of the Cardiovascular Center. He has authored over 300 publications in peer review journals and holds several positions in national and international professional and scientific organisations. His research is focused on the regulation of coronary blood flow and cardiac metabolism in ischemic heart disease.
Vice President Venture Investments, Johnson & Johnson
Zeev Zehavi, Vice President, Venture Investments, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 1999. Mr. Zehavi is based out of offices in Israel and Belgium.
Mr. Zehavi’s background covers an extensive array of healthcare and related businesses. He spent over ten years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd. While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies.